Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Brief Report

Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study

Bertrand Cariou a,*, Matthieu Pichelina, Thomas Goronflot b, Céline Gonfroy c, Michel Marre d, Christelle Raffaitin-Cardin e, Charles Thivolet f, Matthieu Wargnya,b, Samy Hadjadja, Pierre Gourdy g, for the CORONADO investigators

a L'institut du thorax, UNIV Nantes, CHU Nantes, CNRS, Inserm, Département d'Endocrinologie, Diabétologie et Nutrition, CIC Inserm 1413, Hôpital Guillaume et René Laennec, Nantes, France
b CHU de Nantes, CIC Inserm 1413, Clinique des Données, Nantes, France
c Service d'Endocrinologie, Diabétologie, CH de Pontoise, Pontoise, France
d Clinique Ambroise Paré Neuilly-sur-Seine, Centre de Recherches des Cordeliers, Université Paris Diderot, Paris, France
e CH Robert Boulin, Libourne, France
f Centre du Diabète DIAB-eCARE, Hospices Civils de Lyon et laboratoire CarMEN, INSERM, INRA, INSA, Université Claude Bernard Lyon 1, Lyon, France
g Département de Diabétologie, Maladies Métaboliques et Nutrition, CHU de Toulouse et UMR1048/I2MC, Université de Toulouse, Toulouse, France

ARTICLE INFO

Article history:
Received 23 November 2020
Received in revised form 22 January 2021
Accepted 28 January 2021
Available online 10 February 2021

Keywords:
COVID-19
New-onset diabetes
Hospital
Death
Tracheal intubation

ABSTRACT

In patients with diabetes hospitalized for COVID-19 in CORONADO study, 2.8% had a newly discovered diabetes (NDD): mean age 60.2 ± 12.5 years and HbA1C 9.0 ± 2.5%. When compared with center, age and sex-matched patients with established type 2 diabetes, NDD was not significantly associated with a more severe COVID-19 prognosis.

© 2021 Elsevier B.V. All rights reserved.
1. Introduction

It is now well-established that diabetes is a risk factor for increased coronavirus disease 2019 (COVID-19) severity, including higher mortality rate [1–4]. Since the beginning of the pandemic some cases of newly-diagnosed diabetes (NDD) had been observed in patients with COVID-19 [5–7], highlighting a bidirectional relationship between COVID-19 and diabetes [8]. Moreover, it has been suggested that patients with NDD had a worsened prognosis than those with previously established diabetes [3,9,10].

The aim of the current post-hoc analysis is to describe the phenotypic characteristics of subjects with NDD in the nationwide CORONADO study [11].

2. Material and methods

2.1. Study design and participants

The aim of the CORONADO study (clinicaltrials.gov NCT04324736) was to describe the phenotypic characteristics and prognosis of patients with diabetes admitted with COVID-19 between March 10 and April 10, 2020 in 68 French centers. The protocol obtained all regulatory approvals and the design was previously reported [11]. Briefly, inclusion criteria were (i) hospitalization for biologically (positive SARS-CoV-2 PCR) and/or clinically/radiologically confirmed COVID-19; (ii) personal history of diabetes (based on medical record and/or routine use of antidiabetic drugs) or NDD. NDD definition was based on HbA1C ≥ 6.5% [48 mmol/mol] measured during the first week of hospitalization and the absence of personal history of diabetes or diabetic retinopathy (Flow Chart in Figure S1).

2.2. Data collection and outcomes

Data collection was retrospectively performed from medical files of all COVID-19 inpatients and by contacting the patient’s general and/or specialist practitioners, regular pharmacist and biomedical laboratory. The primary outcome combined tracheal intubation for mechanical ventilation and/or death within 7 days of admission. Secondary outcomes notably included death and tracheal intubation taken separately, and hospital discharge. A secondary time point was considered at day 28 for all patients alive and not discharged within 7 days.

2.3. Statistical analysis

NDD patients were matched with up to three patients with T2D on center, sex and age (±5 y). Characteristics are presented as mean ± SD, median [25th-75th percentile] or N (%). P-values were computed using Student-t tests, Mann-Whitney-Wilcoxon tests or Fisher tests. In the matched sample, we used logistic regression models to estimate ORs with 95%CI. Analyses were performed using statistical software R, version 4.0.2.

3. Results

3.1. Phenotypic characteristics of patients with NDD

Among 2,951 CORONADO participants, 2,820 could be analyzed regarding the primary outcome. After a careful review of the medical files, 80 patients (2.8%) were identified as having NDD (Figure S1).

The main clinical characteristics of all NDD patients are shown in supplemental Table 1. Median BMI (25th-75th percentile) was 27.7 (24.9–31.2) kg/m2 and mean HbA1C was 9.0 ± 2.5% [75.1 ± 27.2 mmol/mol]. Compared to patients with established T2D (n = 2237), those with NDD were younger (60.2 ± 12.5 vs 70.5 ± 12.3 yrs, p < 0.001) and more frequently from African or Caribbean origin (31.1 vs 16.7%, p = 0.0055).

In order to identify specific phenotypic characteristics associated to NDD, we have been able to match 67 patients with NDD to 176 patients with established T2D on age, sex and center. As shown in Table 1, the median diabetes duration of patients with T2D was 9 years, with 35.8% under insulin therapy. Patients with NDD had less comorbidities than those with T2D with significantly less hypertension, dyslipidemia and CV diseases, as well as anti-hypertensive drugs and statins. Median BMI was numerically lower in NDD (27.9 vs 29.9 kg/m2 in T2D, p = 0.11), while HbA1C was numerically higher (8.9% vs 8.4% in T2D, p = 0.29). The time between the onset of COVID-19 symptoms and hospitalization was longer in NDD compared to T2D (6 vs 5 days, P = 0.019). The CRP level was significantly higher in patients with NDD, while plasma glucose levels on admission was not different (Table 1).

3.2. COVID-19-related outcomes in patients with NDD

Finally, we compared the occurrence of major clinical outcomes within 7 and 28 days between patients with NDD and with established T2D. As shown in Figure 1, there was no statistically significant difference regarding the composite primary outcome, as well as tracheal intubation or death, between the two groups. There was significantly less discharge in NDD group within 7 days (OR: 0.39 [0.17–0.96]), but the difference was not significant within 28 days (OR: 0.69 [0.37–1.31]).

4. Discussion

In the present analysis of the CORONADO study, we found that NDD occurred in only 2.8% of patients with diabetes hospitalized for COVID-19. This frequency is much lower than those previously reported in Chinese studies, ranging from 16% [12] to 21% [9], but closer to that of 5% reported in a study from Italy [13]. Of note, ethnicity data showed that NDD was more prevalent than T2D in African-Caribbean people but this needs to be confirmed in larger cohorts.

Importantly, we found that the severity of COVID-19 was not different in patients with NDD and age-, center- and sex-matched subjects with established T2D. In contrast to
| Patient characteristics | NDD patients  
(n = 80) | Matched Sample  
(n = 243) | OR or delta (95%CI) | p-value | SMD |
|------------------------|-------------|----------------|-----------------|---------|-----|
| Sex                    | 26/80 (32.5%) | 24/67 (35.8%) | 62/176 (35.2%) | 1.03 (0.57–1.85) | 0.9311 | 1.2 |
| Age                    | 60.2±12.5   | 61.9±11.3     | 64.1±10.7       | 0.98 (0.96–1.01) | 0.1711 | 19.2 |
| Ethnical origin        |             |               |                 |         |     |
| EU                     | 29/61 (47.5%) | 27/51 (52.9%) | 55/146 (35.2%) | 1.00    |     |
| MENA                   | 11/61 (18%)  | 9/51 (17.6%)  | 38/146 (26%)    | 0.48 (0.20–0.14) | 0.0968 |     |
| AC                     | 19/61 (31.1%) | 13/51 (25.5%) | 40/146 (27.4%) | 0.66 (0.30–1.44) | 0.2981 |     |
| AS                     | 2/61 (3.3%)  | 2/51 (3.9%)   | 13/146 (8.9%)   | 0.31 (0.07–1.49) | 0.1445 |     |
| BMI (kg/m^2)           | 27.7 [24.9; 31.2] | 27.9 [25.2; 31.7] | 29.9 [26.2; 33.9] | 0.77 (0.56–1.06) | 0.1092 | 27.9 |
| HbA1c (mmol)           | 75.1±27.2   | 73.8±27.4     | 68.8±26.2       | 1.01 (0.99–1.02) | 0.2912 | 18.6 |
| Hypertension           | 30/78 (38.5%) | 27/65 (41.5%) | 139/175 (79.4%) | 0.18 (0.10–0.34) | <10^{-4} | 84.1 |
| Dyslipidemia           | 10/78 (12.8%) | 8/65 (12.3%)  | 85/173 (49.1%)  | 0.15 (0.07–0.32) | <10^{-4} | 87.1 |
| Current tobacco use    | 3/66 (4.5%)  | 2/55 (3.6%)   | 12/148 (8.1%)   | 0.43 (0.09–1.98) | 0.2766 | 19.1 |
| Cardiovascular diseases^a | 9/69 (13.0%) | 8/58 (13.8%)  | 62/170 (36.5%)  | 0.28 (0.12–0.63) | 0.002 | 54.2 |
| Active cancer          | 3/76 (3.9%)  | 3/64 (4.7%)   | 10/172 (5.8%)   | 0.80 (0.21–0.99) | 0.7364 | 5.1  |
| COPD                   | 3/77 (3.9%)  | 3/64 (4.7%)   | 21/173 (12.1%)  | 0.36 (0.10–1.24) | 0.1041 | 27.1 |
| Treated OSA            | 3/72 (4.2%)  | 2/60 (3.3%)   | 25/164 (15.2%)  | 0.19 (0.04–0.84) | 0.0279 | 41.9 |
| Diabetes duration (years) | –            | –             | –               | –       |     |
| Routine medication     |             |               |                 |         |     |
| Metformin              | –            | –             | 121/176 (68.8%) | –       | –    |
| Sulfonylureas          | –            | –             | 47/176 (26.7%)  | –       | –    |
| DPP4 inhibitors        | –            | –             | 42/176 (23.9%)  | –       | –    |
| GLP-1 RA               | –            | –             | 26/176 (14.8%)  | –       | –    |
| Insulin therapy        | –            | –             | 63/176 (35.8%)  | –       | –    |
| Thiazide diuretics     | 7/80 (8.8%)  | 5/67 (7.5%)   | 41/176 (23.3%)  | 0.27 (0.1–0.7) | 0.0077 | 45   |
| Loop diuretics         | 3/80 (3.8%)  | 2/67 (3.0%)   | 24/176 (13.6%)  | 0.19 (0.04–0.85) | 0.0294 | 39.3 |
| Potassium-sparing diuretics | 1/80 (1.2%) | 1/67 (1.5%)   | 10/176 (5.7%)   | 0.25 (0.03–2.00) | 0.1923 | 22.7 |
| ARBs and/or ACE inhibitors | 18/80 (22.5%) | 15/67 (22.4%) | 100/176 (56.8%) | 0.22 (0.11–0.42) | <10^{-4} | 57.2 |
| Beta-blockers          | 5/80 (6.2%)  | 4/67 (6.0%)   | 54/176 (30.7%)  | 0.14 (0.05–0.41) | <0.001 | 67.4 |
| Calcium-channel inhibitor | 8/80 (10.0%) | 6/67 (9.0%)   | 57/176 (32.4%)  | 0.21 (0.08–0.50) | <0.001 | 60.4 |
| Statins                | 8/80 (10.0%) | 7/67 (10.4%)  | 83/176 (47.2%)  | 0.13 (0.06–0.30) | <0.001 | 88.7 |
| Anti-platelet agent    | 8/80 (10.0%) | 7/67 (10.4%)  | 70/176 (39.8%)  | 0.18 (0.08–0.41) | <0.001 | 71.9 |
| Anticoagulant          | 1/80 (1.2%)  | 1/67 (1.5%)   | 33/176 (19.0%)  | 0.10 (0.01–0.76) | 0.0262 | 45.7 |
| Oral corticosteroids   | 3/80 (3.8%)  | 3/67 (4.5%)   | 11/176 (6.2%)   | 0.70 (0.19–2.6) | 0.5979 | 7.9  |
| Symptoms on admission  |             |               |                 |         |     |
| Positive SARS-CoV-2 PCR | 71/78 (91.0%) | 59/65 (90.8%) | 166/175 (94.9%) | 0.53 (0.18–1.56) | 0.2514 | 15.9 |
| COVID-related symptoms | 77/80 (96.2%) | 64/67 (95.5%) | 174/176 (98.9%) | 0.25 (0.04–1.5) | 0.1284 | 20.3 |
| Duration of symptoms on admission | 7 [4; 9] | 6 [4; 8] | 5 [3; 7.2] | 1.08 (1.01–1.16) | 0.0185 | 34.1 |
| Fever                  | 67/78 (85.9%) | 56/66 (84.8%) | 133/173 (76.9%) | 1.68 (0.79–3.60) | 0.1789 | 20.4 |
| Asthenia               | 51/77 (66.2%) | 43/65 (66.2%) | 112/165 (67.9%) | 0.92 (0.5–1.70) | 0.8016 | 3.7  |
| Cough                  | 64/78 (82.1%) | 53/65 (81.5%) | 117/172 (68.0%) | 2.08 (1.03–4.20) | 0.0419 | 31.5 |
| Cephalalgia            | 14/76 (18.4%) | 11/64 (17.2%) | 34/162 (21.0%)  | 0.78 (0.37–1.66) | 0.5199 | 9.7   |
| Dyspnoea               | 58/79 (73.4%) | 50/66 (75.8%) | 126/173 (72.8%) | 1.17 (0.61–2.24) | 0.6465 | 6.7  |
## Table 1 – (continued)

| Patient characteristics | NDD patients (n = 80) | Matched Sample (n = 243) | Controls: patients with T2D (n = 176) | OR or delta (95%CI) | p-value | SMD |
|-------------------------|-----------------------|--------------------------|--------------------------------------|--------------------|---------|-----|
| Rhinitis and/or pharyngeal symptoms | 8/71 (11.3%) | 7/62 (11.3%) | 19/161 (11.8%) | 0.95 (0.38–2.39) | 0.9152 | 1.6 |
| Ageusia and/or anosmia | 17/69 (24.6%) | 14/59 (23.7%) | 31/159 (19.5%) | 1.28 (0.63–2.63) | 0.4934 | 10.3 |
| Digestive disorder | 24/76 (31.6%) | 19/63 (30.2%) | 46/169 (27.2%) | 1.15 (0.61–2.18) | 0.6576 | 6.5 |

### Biological parameters

| Parameter                              | NDD patients (n = 80) mean ± SD or median [IQR] | Matched Sample (n = 243) mean ± SD or median [IQR] | Controls: patients with T2D (n = 176) mean ± SD or median [IQR] | OR or delta (95%CI) | p-value | SMD |
|----------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|--------------------|---------|-----|
| Plasma glucose on admission (mg/dL)    | 173 [129; 28]                                  | 170 [128; 256]                                  | 173 [131; 231]                                  | 1.25 (0.91–1.71)   | 0.1623 | 28.8 |
| eGFR (CKD-EPI, mL/min)                 | 87.4 [68.9; 99.1]                              | 87.8 [68.3; 99.5]                              | 77.4 [51.8; 96.3]                              | 1.59 (1.1–2.29)    | 0.0131 | 39.4 |
| ALT (% ULN)                            | 0.79 [0.50; 1.34]                              | 0.84 [0.52; 1.36]                              | 0.77 [0.48; 1.21]                              | 1.05 (0.79–1.39)   | 0.7495 | 7.7 |
| AST (% ULN)                            | 1.27 [0.85; 2.3]                               | 1.26 [0.85; 2.3]                               | 1.2 [0.91; 1.75]                               | 1.06 (0.8–1.4)     | 0.702  | 9.4 |
| Hemoglobin (g/dL)                      | 14.0 [13; 15.3]                                | 13.9 [13; 15.2]                                | 13.1 [11.7; 14.4]                              | 1.88 (1.31–2.69)   | 0.0006 | 56  |
| White cells count (G/L)                | 6960 [5440; 8500]                              | 7040 [5810; 8890]                              | 6490 [5000; 8480]                              | 1.28 (0.96–1.70)   | 0.0955 | 22.7 |
| Lymphocyte count (G/L)                 | 1020 [785; 1300]                               | 1000 [740; 1300]                               | 1150 [820; 1622]                               | 0.79 (0.58–1.07)   | 0.1345 | 31.1 |
| Platelet cell count (G/L)              | 204 [159; 258]                                 | 204 [161; 256]                                 | 203 [166; 246]                                 | 1.12 (0.84–1.5)    | 0.4316 | 13.8 |
| CRP (mg/L)                             | 107 [2; 179]                                   | 108 [6; 189]                                   | 95 [4; 153]                                    | 1.37 (1.00–1.88)   | 0.0492 | 20  |
| LDH (UI/L)                             | 484 [363; 647]                                 | 484 [359; 647]                                 | 397 [300; 534]                                 | 1.66 (0.93–2.94)   | 0.0855 | 2.5 |
| CPK (UI/L)                             | 139 [87; 290]                                  | 136 [82; 304]                                  | 154 [87; 421]                                  | 0.87 (0.6–1.26)    | 0.4555 | 22.6 |

Characteristics are presented as N (%) for categorical variables and as mean ± SD. for continuous variables or median [IQR] if non-normally distributed. Univariable associations were estimated using Fisher exact tests, Student-t tests or Mann-Whitney-Wilcoxon tests, respectively.

Abbreviations: EU (Europid); MENA (Middle East North Africa); AC (African or Caribbean); AS (Asian); HbA1c corresponds to the glycated hemoglobin determined in the 6 months prior to or in the first 7 days following hospital admission; COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apnea; DPP4-inhibitors, Dipeptidyl peptidase 4-inhibitors; GLP-1RA, Glucagon-Like Peptide 1-Receptor Agonist; CCB, calcium channel blocker; ARB, angiotensin-2 receptor blocker; ACE-Inhibitors, angiotensin converting enzyme-inhibitors; eGFR, estimated glomerular filtration rate, according to the CKD-EPI formula; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase; CPK, creatine phosphokinase; ULN, Upper limit of normal; SMD, Standardized Mean Difference.

*Cardiovascular diseases were defined as history of one or more of the following comorbidities: acute coronary syndrome, coronary artery disease revascularization, transient ischemic attack and/or lower limber artery revascularization.
previous reports [9,13], our results did not confirm a worsened COVID-19 prognosis in NDD compared to established T2D. It should be underlined, however, that patients with NDD had significantly less comorbidities (i.e. CV diseases, hypertension or dyslipidemia) than those with established T2D. These potential confounding factors were not taken into account in our matching process. Another potential explanation for this discrepancy is the severity of the COVID-19 in T2D which appears more pronounced in CORONADO with a mortality rate of 17.6% within 28 days compared to 11.2% in the study of Li et al. [9] and 14.0% in those of Fadini et al. [13]. It should be underlined however that the mortality rate was also similar in NDD and established diabetes in the latter study in which the severity was mainly driven by admission in ICU [13]. We also found that tracheal intubation was numerically, but not statistically, higher and that early discharge was significantly lower in NDD compared to established T2D. In accordance with the prominent role of hyperglycemia per se as a prognosis factor for COVID-19 [14], the admission plasma glucose levels were not different between NDD and T2D groups. Some differences regarding routine treatments between patients with NDD or T2D might also have impacted the outcomes. For instance, metformin was associated with a reduced risk of death in patients with T2D in CORONADO [15]. Conversely, statin use was reported to be associated with a worse prognosis in CORONADO [16].

Our study displays some limitations, notably its observational and post-hoc design. Since we cannot guarantee that biological screening with HbA1C was systematically performed in all patients, an underestimation of the NDD frequency cannot be excluded. Finally, information on diabetes management and evolution following the admission are lacking, especially regarding the use and the dose of glucose lowering therapies as well as the quality of glycemic control.

As highlighted by some authors [8,17], some dedicated prospective studies are warranted to assess more precisely the link between NDD and COVID-19 and to limit confounding biases due to observational design.

Acknowledgments

We thank the sponsor of the study (DRCI [délegation à la recherche clinique et à l’innovation] CHU Nantes), the Clinical Project Manager (M. Saignes) and assistant (J. Saunier), Clinical Research Associates (S. El Andaloussi, J. Martin-Gauthier, E. Rebouilleau) and data-managers (B. Guyomarc’h, T. Roman). We acknowledge all medical and clinical research staff involved in the diagnosis and treatment of patients with COVID-19 in participating centers. We thank all of the general practitioners, specialists, pharmacists and biological laboratories responsible for hospitalized patients for providing additional medical information to investigators. We thank the Société Francophone du Diabète (SFD) and Société Française d’Endocrinologie (SFE) for disseminating the study design and organization, and the Fédération Française des
Diabétiques (FFD) for participating in the organization of the study.

5. Funding Sources

This study received the following funding: the Fondation Francophone de Recherche sur le Diabète (FFRD), supported by Novo Nordisk, MSD, Abbott, AstraZeneca, Lilly and FFD (Fédération Française des Diabétiques) – CORONADO initiative emergency grant; Société Francophone du Diabète (SFD) – CORONADO initiative emergency grant; Air Liquide Health Care International. CORONADO initiative emergency grant; Allergan. CORONADO initiative emergency grant; AstraZeneca. CORONADO initiative emergency grant; ELIVIE. CORONADO initiative emergency grant; FORTIL. CORONADO initiative emergency grant; Lifescan. CORONADO initiative emergency grant; Nantes Métropole. CORONADO initiative emergency grant; NHC. CORONADO initiative emergency grant; Novo Nordisk. CORONADO initiative emergency grant; Sanofi. CORONADO emergency grant; PHRC National COVID-19 Hospitalization and Care Organization Division (DHOS) as part of the Hospital Clinical Research Program (PHRC COVID-19-20-0138). All research facilities are acknowledged for providing research associates and research technicians for clinical investigations pro bono. The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the study.

Conflict Of Interest

BC reports grants, non-financial support or personal fees from Abbott, Air Liquid, Allergan, Amgen, Akcea AstraZeneca, Eliivie, Fortil, Pierre Fabre, Genfit, Gilead, Lifescan, Eli Lilly, Merck Sharpe Dome, NHC, Novo Nordisk, Regeneron and Sanofi. MP reports grants, non-financial support or personal fees from Air Liquid, Allergan, Amgen, Eliivie, Fortil, Lifescan, NHC, Novo Nordisk, and Sanofi. MW reports grants, personal fees from Air Liquid, Allergan, Elivie, Fortis, Lifescan, NHC, Novo Nordisk, and Sanofi. SH reports grants, non-financial support or personal fees from Air Liquid, Allergan, AstraZeneca, Bayer, Boehringer Ingelheim, Dinno Santé, Eliivie, Fortil, Eli Lilly, Lifescan, LVL, Merck Sharpe Dome, NHC, Novartis, Pierre Fabre Santé, Sanofi, Servier, and Valbiatrics. PG reports grants or personal fees from Abbott, Air Liquid, Allergan, Amgen, Astra-Zeneca, Boehringer Ingelheim, Eliivie, Fortil, Eli Lilly, Lifescan, Merck Sharp and Dohme, Mundipharma, NHC, Novo Nordisk, Sanofi, and Servier. The other authors had nothing to disclose.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.diabres.2021.108695.

REFERENCES

[1] Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole population study. Lancet Diabetes Endocrinol 2020;8:813–22.

[2] Zhu L, She ZG, Cheng X, Qin JI, Zhang XJ, Cai J, et al. Association of blood glucose and outcomes in patients with COVID-19 an pre-existing type 2 diabetes. Cell Metab 2020;31:1068–77.

[3] Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020;14:813–21.

[4] Kubjane M, McCreedy N, Cariou B, Rubio MA, Panton UH, Hvid C, et al. Association of diabetes and severe COVID-19 outcomes: a rapid review and meta-analysis. J Endocrinol Metab 2020;10:118–30.

[5] Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract 2020;164. 108166.

[6] Armien E, Aziz U, Qamar S, Nasir S, Nethaji C, Negus R, et al. Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. Lancet Diabetes Endocrinol 2020;8:660–3.

[7] Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020. https://doi.org/10.1111/dom.14057.

[8] Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-onset diabetes in Covid-19. N Engl J Med 2020;383:789–90.

[9] Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab 2020. https://doi.org/10.1111/dom.14099.

[10] Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract 2020;167. 108382.

[11] Cariou B, Hadjadji S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63:1500–15.

[12] Zhang Y, Li H, Zhang J, Cao Y, Zhao X, Yu N, et al. A single-centre, retrospective, observational study in Wuhan. Diabetes Obes Metab 2020;22:1443–54.

[13] Fadini GP, Morieri ML, Boscari F, Fioretto P, Fiossetto P, Maran A, Busetto L, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract 2020;168. 108374.

[14] Ceriello A, Nigris VD, Prattichizzo F. Why is hyperglycemia worsening COVID-19 and its prognosis?. Diabetes Obes Metab 2020. https://doi.org/10.1111/dom.14096.

[15] Lalau JD, Al-Salameh A, Hadjadj S, et al. Metformin use is associated with a lower risk of COVID-19 and its prognosis?. Diabetes Obes Metab 2020. https://doi.org/10.1111/dom.1417.

[16] Cariou B, Goronflot T, Rimbert A, et al. Routine use of statins in patients with COVID-19: a retrospective case series. Lancet Diabetes Endocrinol 2020;8:660–3.

[17] Gentile S, Strollo F, Mambo A, Ceriello A. COVID-19, ketoacidosis and new-onset diabetes: are there possible cause and effect relationship among them?. Diabetes Obes Metab 2020. https://doi.org/10.1111/dom.1417.